United States · FDA National Drug Code directory
TAVALISSE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 71332-002_78828503-b88f-4e3d-9add-8b738c4cf28e
- Product NDC
- 71332-002
- Form
- TABLET
- Composition / generic term
- FOSTAMATINIB
- Labeler
- Rigel Pharmaceuticals, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20180509
- Source listing expiry
- 20261231
Source-listed ingredients
- FOSTAMATINIB — 150 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 60 TABLET in 1 BOTTLE (71332-002-01) · 71332-002-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →